Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 140

1.

Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats.

Levin ED, Wells C, Johnson JE, Rezvani AH, Bymaster FP, Rose JE.

Eur J Pharmacol. 2015 Oct 5;764:30-7. doi: 10.1016/j.ejphar.2015.06.041. Epub 2015 Jun 20.

2.

Antipsychotic-like effect of the muscarinic acetylcholine receptor agonist BuTAC in non-human primates.

Andersen MB, Croy CH, Dencker D, Werge T, Bymaster FP, Felder CC, Fink-Jensen A.

PLoS One. 2015 Apr 16;10(4):e0122722. doi: 10.1371/journal.pone.0122722. eCollection 2015.

3.

Biopharmaceutical characterization, metabolism, and brain penetration of the triple reuptake inhibitor amitifadine.

Bymaster FP, Chao P, Schulze H, Tran PV, Marshall RD.

Drug Metab Lett. 2013 Mar;7(1):23-33.

PMID:
23826879
4.

A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder.

Upadhyaya HP, Desaiah D, Schuh KJ, Bymaster FP, Kallman MJ, Clarke DO, Durell TM, Trzepacz PT, Calligaro DO, Nisenbaum ES, Emmerson PJ, Schuh LM, Bickel WK, Allen AJ.

Psychopharmacology (Berl). 2013 Mar;226(2):189-200. doi: 10.1007/s00213-013-2986-z. Epub 2013 Feb 9. Review.

5.

Muscarinic mechanisms in psychotic disorders.

McKinzie DL, Bymaster FP.

Handb Exp Pharmacol. 2012;(213):233-65. doi: 10.1007/978-3-642-25758-2_9. Review.

PMID:
23027418
6.

Pharmacological characterization of the norepinephrine and dopamine reuptake inhibitor EB-1020: implications for treatment of attention-deficit hyperactivity disorder.

Bymaster FP, Golembiowska K, Kowalska M, Choi YK, Tarazi FI.

Synapse. 2012 Jun;66(6):522-32. doi: 10.1002/syn.21538. Epub 2012 Feb 22.

PMID:
22298359
7.

Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.

Golembiowska K, Kowalska M, Bymaster FP.

Synapse. 2012 May;66(5):435-44. doi: 10.1002/syn.21531. Epub 2012 Feb 15.

PMID:
22213370
8.

Lu AE58054, a 5-HT6 antagonist, reverses cognitive impairment induced by subchronic phencyclidine in a novel object recognition test in rats.

Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP, DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM.

Int J Neuropsychopharmacol. 2010 Sep;13(8):1021-33. doi: 10.1017/S1461145710000659. Epub 2010 Jun 23.

PMID:
20569520
9.

Antipsychotic drugs: comparison in animal models of efficacy, neurotransmitter regulation, and neuroprotection.

Lieberman JA, Bymaster FP, Meltzer HY, Deutch AY, Duncan GE, Marx CE, Aprille JR, Dwyer DS, Li XM, Mahadik SP, Duman RS, Porter JH, Modica-Napolitano JS, Newton SS, Csernansky JG.

Pharmacol Rev. 2008 Sep;60(3):358-403. doi: 10.1124/pr.107.00107. Review. Erratum in: Pharmacol Rev. 2008 Dec;60(4):582.

10.

Allosteric modulation of the muscarinic M4 receptor as an approach to treating schizophrenia.

Chan WY, McKinzie DL, Bose S, Mitchell SN, Witkin JM, Thompson RC, Christopoulos A, Lazareno S, Birdsall NJ, Bymaster FP, Felder CC.

Proc Natl Acad Sci U S A. 2008 Aug 5;105(31):10978-83. doi: 10.1073/pnas.0800567105. Epub 2008 Aug 4.

11.

Selective muscarinic receptor agonist xanomeline as a novel treatment approach for schizophrenia.

Shekhar A, Potter WZ, Lightfoot J, Lienemann J, Dubé S, Mallinckrodt C, Bymaster FP, McKinzie DL, Felder CC.

Am J Psychiatry. 2008 Aug;165(8):1033-9. doi: 10.1176/appi.ajp.2008.06091591. Epub 2008 Jul 1.

PMID:
18593778
12.

Zonisamide prevents olanzapine-associated hyperphagia, weight gain, and elevated blood glucose in rats.

Wallingford NM, Sinnayah P, Bymaster FP, Gadde KM, Krishnan RK, McKinney AA, Landbloom RP, Tollefson GD, Cowley MA.

Neuropsychopharmacology. 2008 Nov;33(12):2922-33. doi: 10.1038/npp.2008.9. Epub 2008 Mar 5.

13.

Towards a muscarinic hypothesis of schizophrenia.

Raedler TJ, Bymaster FP, Tandon R, Copolov D, Dean B.

Mol Psychiatry. 2007 Mar;12(3):232-46. Epub 2006 Dec 5. Review.

PMID:
17146471
14.

The procholinergic effects of the atypical antipsychotic olanzapine are independent of muscarinic autoreceptor inhibition.

Tzavara ET, Bymaster FP, Nomikos GG.

Mol Psychiatry. 2006 Jul;11(7):619-21. No abstract available.

PMID:
16801977
15.

Cholinergic dysfunction in a mouse model of Alzheimer disease is reversed by an anti-A beta antibody.

Bales KR, Tzavara ET, Wu S, Wade MR, Bymaster FP, Paul SM, Nomikos GG.

J Clin Invest. 2006 Mar;116(3):825-32. Epub 2006 Feb 23.

16.

Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat.

Swanson CJ, Perry KW, Koch-Krueger S, Katner J, Svensson KA, Bymaster FP.

Neuropharmacology. 2006 May;50(6):755-60. Epub 2006 Jan 19.

PMID:
16427661
17.

Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine.

Tzavara ET, Bymaster FP, Overshiner CD, Davis RJ, Perry KW, Wolff M, McKinzie DL, Witkin JM, Nomikos GG.

Mol Psychiatry. 2006 Feb;11(2):187-95.

PMID:
16231039
18.

Preclinical pharmacology of FMPD [6-fluoro-10-[3-(2-methoxyethyl)-4-methyl-piperazin-1-yl]-2-methyl-4H-3-thia-4,9-diaza-benzo[f]azulene]: a potential novel antipsychotic with lower histamine H1 receptor affinity than olanzapine.

Rasmussen K, Benvenga MJ, Bymaster FP, Calligaro DO, Cohen IR, Falcone JF, Hemrick-Luecke SK, Martin FM, Moore NA, Nisenbaum LK, Schaus JM, Sundquist SJ, Tupper DE, Wiernicki TR, Nelson DL.

J Pharmacol Exp Ther. 2005 Dec;315(3):1265-77. Epub 2005 Sep 1.

PMID:
16141369
19.

Case history: the discovery of fluoxetine hydrochloride (Prozac).

Wong DT, Perry KW, Bymaster FP.

Nat Rev Drug Discov. 2005 Sep;4(9):764-74. Review.

PMID:
16121130
20.

The dual transporter inhibitor duloxetine: a review of its preclinical pharmacology, pharmacokinetic profile, and clinical results in depression.

Bymaster FP, Lee TC, Knadler MP, Detke MJ, Iyengar S.

Curr Pharm Des. 2005;11(12):1475-93. Review.

PMID:
15892657
21.

Amantadine for weight gain associated with olanzapine treatment.

Deberdt W, Winokur A, Cavazzoni PA, Trzaskoma QN, Carlson CD, Bymaster FP, Wiener K, Floris M, Breier A.

Eur Neuropsychopharmacol. 2005 Jan;15(1):13-21.

PMID:
15572269
22.

Treatment of glossodynia with olanzapine.

Gick CL, Mirowski GW, Kennedy JS, Bymaster FP.

J Am Acad Dermatol. 2004 Sep;51(3):463-5.

PMID:
15337994
23.

M4 muscarinic receptors regulate the dynamics of cholinergic and dopaminergic neurotransmission: relevance to the pathophysiology and treatment of related CNS pathologies.

Tzavara ET, Bymaster FP, Davis RJ, Wade MR, Perry KW, Wess J, McKinzie DL, Felder C, Nomikos GG.

FASEB J. 2004 Sep;18(12):1410-2. Epub 2004 Jul 1.

PMID:
15231726
24.

Clinical assessment of norepinephrine transporter blockade through biochemical and pharmacological profiles.

Vincent S, Bieck PR, Garland EM, Loghin C, Bymaster FP, Black BK, Gonzales C, Potter WZ, Robertson D.

Circulation. 2004 Jun 29;109(25):3202-7. Epub 2004 Jun 7.

PMID:
15184278
25.

The Comparative Peripheral Anticholinergic-Like Adverse Event Profiles of Olanzapine and Risperidone.

Kennedy JS, Bymaster FP, Basson BR, Gilmore JA, Tran PV.

Prim Care Companion J Clin Psychiatry. 2000 Aug;2(4):122-126.

26.
27.

Duloxetine (Cymbalta), a dual inhibitor of serotonin and norepinephrine reuptake.

Bymaster FP, Beedle EE, Findlay J, Gallagher PT, Krushinski JH, Mitchell S, Robertson DW, Thompson DC, Wallace L, Wong DT.

Bioorg Med Chem Lett. 2003 Dec 15;13(24):4477-80.

PMID:
14643350
28.

Muscarinic mechanisms of antipsychotic atypicality.

Bymaster FP, Felder CC, Tzavara E, Nomikos GG, Calligaro DO, Mckinzie DL.

Prog Neuropsychopharmacol Biol Psychiatry. 2003 Oct;27(7):1125-43. Review.

PMID:
14642972
29.

Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.

Kennedy JS, Jeste D, Kaiser CJ, Golshan S, Maguire GA, Tollefson G, Sanger T, Bymaster FP, Kinon BJ, Dossenbach M, Gilmore JA, Breier A.

Int J Geriatr Psychiatry. 2003 Nov;18(11):1013-20.

PMID:
14618553
30.

Comparison of effects of dual transporter inhibitors on monoamine transporters and extracellular levels in rats.

Koch S, Hemrick-Luecke SK, Thompson LK, Evans DC, Threlkeld PG, Nelson DL, Perry KW, Bymaster FP.

Neuropharmacology. 2003 Dec;45(7):935-44.

PMID:
14573386
31.

Muscarinic receptors in schizophrenia.

Dean B, Bymaster FP, Scarr E.

Curr Mol Med. 2003 Aug;3(5):419-26. Review.

PMID:
12942995
32.

M1-M5 muscarinic receptor knockout mice as novel tools to study the physiological roles of the muscarinic cholinergic system.

Wess J, Duttaroy A, Zhang W, Gomeza J, Cui Y, Miyakawa T, Bymaster FP, McKinzie L, Felder CC, Lamping KG, Faraci FM, Deng C, Yamada M.

Receptors Channels. 2003;9(4):279-90. Review.

PMID:
12893539
33.

Dysregulated hippocampal acetylcholine neurotransmission and impaired cognition in M2, M4 and M2/M4 muscarinic receptor knockout mice.

Tzavara ET, Bymaster FP, Felder CC, Wade M, Gomeza J, Wess J, McKinzie DL, Nomikos GG.

Mol Psychiatry. 2003 Jul;8(7):673-9.

PMID:
12874603
34.

Duloxetine increases serotonin and norepinephrine availability in healthy subjects: a double-blind, controlled study.

Chalon SA, Granier LA, Vandenhende FR, Bieck PR, Bymaster FP, Joliat MJ, Hirth C, Potter WZ.

Neuropsychopharmacology. 2003 Sep;28(9):1685-93. Epub 2003 May 28.

35.

Muscarinic receptors as a target for drugs treating schizophrenia.

Bymaster FP, Felder C, Ahmed S, McKinzie D.

Curr Drug Targets CNS Neurol Disord. 2002 Apr;1(2):163-81. Review.

PMID:
12769625
36.

Role of specific muscarinic receptor subtypes in cholinergic parasympathomimetic responses, in vivo phosphoinositide hydrolysis, and pilocarpine-induced seizure activity.

Bymaster FP, Carter PA, Yamada M, Gomeza J, Wess J, Hamilton SE, Nathanson NM, McKinzie DL, Felder CC.

Eur J Neurosci. 2003 Apr;17(7):1403-10.

PMID:
12713643
37.

Use of M1-M5 muscarinic receptor knockout mice as novel tools to delineate the physiological roles of the muscarinic cholinergic system.

Bymaster FP, McKinzie DL, Felder CC, Wess J.

Neurochem Res. 2003 Apr;28(3-4):437-42. Review.

PMID:
12675128
38.

New approaches to developing antidepressants by enhancing monoaminergic neurotransmission.

Bymaster FP, McNamara RK, Tran PV.

Expert Opin Investig Drugs. 2003 Apr;12(4):531-43. Review.

PMID:
12665410
39.

The CB1 receptor antagonist SR141716A selectively increases monoaminergic neurotransmission in the medial prefrontal cortex: implications for therapeutic actions.

Tzavara ET, Davis RJ, Perry KW, Li X, Salhoff C, Bymaster FP, Witkin JM, Nomikos GG.

Br J Pharmacol. 2003 Feb;138(4):544-53.

40.

Dual monoamine modulation for improved treatment of major depressive disorder.

Tran PV, Bymaster FP, McNamara RK, Potter WZ.

J Clin Psychopharmacol. 2003 Feb;23(1):78-86. Review. Erratum in: J Clin Psychopharmacol. 2003 Aug;23(4):425.

PMID:
12544378
41.

R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and hypothalamus: an in vivo microdialysis and receptor binding study.

Koch S, Perry KW, Nelson DL, Conway RG, Threlkeld PG, Bymaster FP.

Neuropsychopharmacology. 2002 Dec;27(6):949-59.

42.

Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder.

Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW.

Neuropsychopharmacology. 2002 Nov;27(5):699-711.

43.

Muscarinic agonist-mediated increases in serum corticosterone levels are abolished in m(2) muscarinic acetylcholine receptor knockout mice.

Hemrick-Luecke SK, Bymaster FP, Evans DC, Wess J, Felder CC.

J Pharmacol Exp Ther. 2002 Oct;303(1):99-103.

PMID:
12235238
44.

M1 muscarinic receptor signaling in mouse hippocampus and cortex.

Porter AC, Bymaster FP, DeLapp NW, Yamada M, Wess J, Hamilton SE, Nathanson NM, Felder CC.

Brain Res. 2002 Jul 19;944(1-2):82-9.

PMID:
12106668
45.
46.

Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.

Porter AC, Sauer JM, Knierman MD, Becker GW, Berna MJ, Bao J, Nomikos GG, Carter P, Bymaster FP, Leese AB, Felder CC.

J Pharmacol Exp Ther. 2002 Jun;301(3):1020-4.

PMID:
12023533
47.
48.

The tyramine pressor test may have limited sensitivity, especially in the presence of dual serotonin/norepinephrine uptake inhibition.

Chalon S, Bieck PR, Goldstein DJ, Detke MJ, Bymaster FP, Potter WZ, Demitrack MA.

Neuropsychopharmacology. 2002 May;26(5):698-9; author reply 700-1. No abstract available.

49.

Fluoxetine, but not other selective serotonin uptake inhibitors, increases norepinephrine and dopamine extracellular levels in prefrontal cortex.

Bymaster FP, Zhang W, Carter PA, Shaw J, Chernet E, Phebus L, Wong DT, Perry KW.

Psychopharmacology (Berl). 2002 Apr;160(4):353-61. Epub 2002 Jan 29.

PMID:
11919662
50.

Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors.

Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG, Shaw JL, Thompson L, Nelson DL, Hemrick-Luecke SK, Wong DT.

Neuropsychopharmacology. 2001 Dec;25(6):871-80.

Supplemental Content

Loading ...
Support Center